Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Isotonic solution of sodium chloride provides replacement of sodium and chloride ions, maintains extracellular fluid volume, and serves as a vehicle for drug administration. It acts as a source of electrolytes and water for hydration.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion, typical adult dose: 500-1000 mL bolus for volume resuscitation, then rate determined by clinical status; maintenance: 100-200 mL/hour continuous IV infusion.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable; sodium and chloride are endogenous electrolytes. Their half-life depends on renal function and volume status, typically ranging from 6 to 12 hours in healthy individuals, but prolonged in renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal excretion; >99% of filtered sodium and chloride are reabsorbed under normal physiological conditions, with excretion equal to intake. In clinical use, excess sodium and chloride are excreted renally. Biliary/fecal excretion is negligible (<1%).
Category C
Category A/B
Electrolyte
Electrolyte